Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 11, 2011 - Issue 7
Submit an article Journal homepage
146
Views
5
CrossRef citations to date
0
Altmetric
Theme: Schizophrenia - Review

Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?

Maurizio Pompili Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy; McLean Hospital, Harvard Medical School, MA, USA;[email protected]
,
Gianluca Serafini Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy; Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy
,
Marco Innamorati Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy; Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy
,
Elisa Ambrosi Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy; Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy
,
Ludovica Telesforo Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy; Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy
,
Paola Venturini Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy; Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy
,
Gloria Giordano Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy; Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy
,
Michele Battuello Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy; Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy
,
David Lester The Richard Stockton College of New Jersey, NJ, USA; The Richard Stockton College of New Jersey, NJ, USA
&
Paolo Girardi Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy; Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; Department of Psychiatry, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy
 show all
Pages 989-1006 | Published online: 09 Jan 2014
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Adverse metabolic events, such as increased adiposity, hyperglycemia, diabetes mellitus and dyslipidemia, have been associated with treatment using atypical antipsychotic medications. However, the complexity of some of the reports on this problem and marketing efforts in this area may make it difficult for psychiatrists to remain fully and accurately informed about the metabolic complications of atypical antipsychotic therapy. Little is currently known about how psychiatrists view what they have read or heard, how they perceive the available information and how this affects their management of patients with schizophrenia. A number of studies have demonstrated that nonadherence to the medication regimen in schizophrenia is associated with poor symptomatic outcome, increased risk of relapse, more frequent use of compulsory treatment and increased risk of suicide and severe self-harm. Suicide is a major cause of death among schizophrenic patients, and their attitude toward medication can make the difference between a proper therapeutic regimen that protects patients from suicide risk versus discontinuation of treatments that are associated with disabling symptoms, some of which are risk factors for suicide. We review the characteristics of a new drug, asenapine, that may improve adherence in patients as a result of a distinctive receptor profile that may be associated with fewer side effects than other second-generation antipsychotic drugs.

Financial & competing interests disclosure

Maurizio Pompili has served as a consultant to Schering-Plough Italy; Paolo Girardi has served as a consultant to, or has engaged in research collaborations with Organon, Eli Lilly, Janssen, Merck, Bristol-Myers Squibb and Astra-Zeneca Corporations. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 651.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.